Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(2):189–197. doi: 10.1038/bjc.1998.463

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity.

M Chinol 1, P Casalini 1, M Maggiolo 1, S Canevari 1, E S Omodeo 1, P Caliceti 1, F M Veronese 1, M Cremonesi 1, F Chiolerio 1, E Nardone 1, A G Siccardi 1, G Paganelli 1
PMCID: PMC2062912  PMID: 9683292

Abstract

Pretargeting techniques using the avidin-biotin system have shown encouraging results in both diagnostic and therapeutic clinical trials. It has been shown that in cancer therapy the ideal agent to be used for pretargeting should have a plasma half-life longer than avidin and lower immunogenicity than streptavidin in order for these procedures to be applied safely and repeatedly in patients. We prepared a recombinant form of avidin with no carbohydrates and avidins, biochemically modified either by decreasing the positive charges with succinic anhydride or by linking polyethylene glycol (PEG) at three different molar ratios and evaluated their in vivo behaviour after i.p. administration in mice. The succinylation and PEGylation of avidin increased the plasma half-life proportionally to the degree of protein modification. The procedures, however, affected the biotin binding to some extent. The biodistribution studies showed that, for all six time points (ranging from 20 min to 18 h post-injection), the liver and kidney to blood ratios were lower for PEGylated avidins than native, recombinant and succinyl avidin. Recombinant and low PEGylated avidin evoked an immune response in all mice after at least three injections. Native, recombinant and succinyl avidins showed higher serum titres than PEGylated avidins. In conclusion, the conjugation of avidin to PEG chains (n = 7) originates a compound with a suitable blood clearance, low immunogenicity and concurrent low cross-reactivity with avidin.

Full text

PDF
197

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez-Diez T. M., Polihronis J., Reilly R. M. Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin. Nucl Med Biol. 1996 May;23(4):459–466. doi: 10.1016/0969-8051(96)00022-4. [DOI] [PubMed] [Google Scholar]
  2. Bidlingmeyer B. A., Cohen S. A., Tarvin T. L. Rapid analysis of amino acids using pre-column derivatization. J Chromatogr. 1984 Dec 7;336(1):93–104. doi: 10.1016/s0378-4347(00)85133-6. [DOI] [PubMed] [Google Scholar]
  3. Border W. A., Ward H. J., Kamil E. S., Cohen A. H. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest. 1982 Feb;69(2):451–461. doi: 10.1172/JCI110469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bruch R. C., White H. B., 3rd Compositional and structural heterogeneity of avidin glycopeptides. Biochemistry. 1982 Oct 12;21(21):5334–5341. doi: 10.1021/bi00264a033. [DOI] [PubMed] [Google Scholar]
  5. Delgado C., Pedley R. B., Herraez A., Boden R., Boden J. A., Keep P. A., Chester K. A., Fisher D., Begent R. H., Francis G. E. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer. 1996 Jan;73(2):175–182. doi: 10.1038/bjc.1996.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fazio F., Paganelli G. Antibody-guided scintigraphy: targeting of the "magic bullet". Eur J Nucl Med. 1993 Dec;20(12):1138–1140. doi: 10.1007/BF00171010. [DOI] [PubMed] [Google Scholar]
  7. Gitlin G., Bayer E. A., Wilchek M. Studies on the biotin-binding sites of avidin and streptavidin. Tyrosine residues are involved in the binding site. Biochem J. 1990 Jul 15;269(2):527–530. doi: 10.1042/bj2690527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goodwin D. A. Tumor pretargeting: almost the bottom line. J Nucl Med. 1995 May;36(5):876–879. [PubMed] [Google Scholar]
  9. Green N. M. Avidin. Adv Protein Chem. 1975;29:85–133. doi: 10.1016/s0065-3233(08)60411-8. [DOI] [PubMed] [Google Scholar]
  10. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  11. Hnatowich D. J., Virzi F., Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987 Aug;28(8):1294–1302. [PubMed] [Google Scholar]
  12. Kamisaki Y., Wada H., Yagura T., Matsushima A., Inada Y. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther. 1981 Feb;216(2):410–414. [PubMed] [Google Scholar]
  13. Kang Y. S., Saito Y., Pardridge W. M. Pharmacokinetics of [3H]biotin bound to different avidin analogues. J Drug Target. 1995;3(2):159–165. doi: 10.3109/10611869509059215. [DOI] [PubMed] [Google Scholar]
  14. Kaseda N., Uehara Y., Yamamoto Y., Tanaka K. Induction of in situ immune complexes in rat glomeruli using avidin, a native cation macromolecule. Br J Exp Pathol. 1985 Dec;66(6):729–735. [PMC free article] [PubMed] [Google Scholar]
  15. Kobayashi H., Sakahara H., Hosono M., Yao Z. S., Toyama S., Endo K., Konishi J. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. J Nucl Med. 1994 Oct;35(10):1677–1684. [PubMed] [Google Scholar]
  16. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  17. Magnani P., Paganelli G., Modorati G., Zito F., Songini C., Sudati F., Koch P., Maecke H. R., Brancato R., Siccardi A. G. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med. 1996 Jun;37(6):967–971. [PubMed] [Google Scholar]
  18. Marshall D., Pedley R. B., Boden J. A., Boden R., Melton R. G., Begent R. H. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer. 1996 Mar;73(5):565–572. doi: 10.1038/bjc.1996.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Paganelli G., Chinol M., Maggiolo M., Sidoli A., Corti A., Baroni S., Siccardi A. G. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med. 1997 Mar;24(3):350–351. doi: 10.1007/BF01728778. [DOI] [PubMed] [Google Scholar]
  20. Paganelli G., Pervez S., Siccardi A. G., Rowlinson G., Deleide G., Chiolerio F., Malcovati M., Scassellati G. A., Epenetos A. A. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer. 1990 Jun 15;45(6):1184–1189. doi: 10.1002/ijc.2910450632. [DOI] [PubMed] [Google Scholar]
  21. Paganelli G., Stella M., Zito F., Magnani P., De Nardi P., Mangili F., Baratti D., Veglia F., Di Carlo V., Siccardi A. G. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. J Nucl Med. 1994 Dec;35(12):1970–1975. [PubMed] [Google Scholar]
  22. Rosebrough S. F. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. Nucl Med Biol. 1993 Jul;20(5):663–668. doi: 10.1016/0969-8051(93)90037-u. [DOI] [PubMed] [Google Scholar]
  23. Samuel A., Paganelli G., Chiesa R., Sudati F., Calvitto M., Melissano G., Grossi A., Fazio F. Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J Nucl Med. 1996 Jan;37(1):55–61. [PubMed] [Google Scholar]
  24. Sartore L., Caliceti P., Schiavon O., Veronese F. M. Enzyme modification by MPEG with an amino acid or peptide as spacer arms. Appl Biochem Biotechnol. 1991 Jan;27(1):45–54. doi: 10.1007/BF02921514. [DOI] [PubMed] [Google Scholar]
  25. Schechter B., Silberman R., Arnon R., Wilchek M. Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem. 1990 Apr 30;189(2):327–331. doi: 10.1111/j.1432-1033.1990.tb15493.x. [DOI] [PubMed] [Google Scholar]
  26. Shin S. U., Wu D., Ramanathan R., Pardridge W. M., Morrison S. L. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol. 1997 May 15;158(10):4797–4804. [PubMed] [Google Scholar]
  27. Sims G. E., Snape T. J. A method for the estimation of polyethylene glycol in plasma protein fractions. Anal Biochem. 1980 Sep 1;107(1):60–63. doi: 10.1016/0003-2697(80)90492-3. [DOI] [PubMed] [Google Scholar]
  28. Sung C., van Osdol W. W., Saga T., Neumann R. D., Dedrick R. L., Weinstein J. N. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res. 1994 Apr 15;54(8):2166–2175. [PubMed] [Google Scholar]
  29. Wilchek M., Bayer E. A. Avidin-biotin technology ten years on: has it lived up to its expectations? Trends Biochem Sci. 1989 Oct;14(10):408–412. doi: 10.1016/0968-0004(89)90289-2. [DOI] [PubMed] [Google Scholar]
  30. Wilchek M., Bayer E. A. The avidin-biotin complex in bioanalytical applications. Anal Biochem. 1988 May 15;171(1):1–32. doi: 10.1016/0003-2697(88)90120-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES